Celldex Therapeutics
CLDX
76 hedge funds and large institutions have $365M invested in Celldex Therapeutics in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 8 closing their positions.
5,008% more capital invested
Capital invested by funds: $7.15M → $365M (+$358M)
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
185% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $4.61M
69% more funds holding
Funds holding: 45 → 76 (+31)
54.61% more ownership
Funds ownership: 22.58% → 77.19% (+55%)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$12.1M |
| 2 |
RI
RTW Investments
New York
|
+$11.6M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.86M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$8.86M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.76M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
US Bancorp
Minneapolis,
Minnesota
| – | +$27 | +6 | New |
|
|
CAN
77
Cetera Advisor Networks
El Segundo,
California
| – | +$124 | +28 | New |
|
CLDX Hedge Fund Activity: Q2 2020 in Review
76 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2020, worth a combined $365M — up 5,008% from $7.15M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CLDX positions and 8 closed out — a net gain of 31 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $12.1M. The largest seller was Meditor Group, cutting an estimated $993K.
- 76 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2020, up from 45 in Q1 2020.
- Funds reported $365M of Celldex Therapeutics stock for Q2 2020, up 5,008% quarter-over-quarter.
- 39 funds opened new Celldex Therapeutics positions in Q2 2020 and 8 closed out, a net change of +31 holders.
- The largest Celldex Therapeutics buyer in Q2 2020 was BVF Inc, an estimated $12.1M added.
- The largest Celldex Therapeutics seller in Q2 2020 was Meditor Group, an estimated $993K sold.
Based on aggregated 13F filings for Q2 2020.